Letter by Takov et al Regarding Article, “Fabrication of Synthetic Mesenchymal Stem Cells for the Treatment of Acute Myocardial Infarction in Mice”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We were interested by the Luo et al1 article on the production of synthetic mesenchymal stem cells recently published in the Circulation Research journal. The authors manufactured microparticles consisting of poly(lactic-co-glycolic acid)–incorporated mesenchymal stem cell (MSC)-conditioned medium. They used membranes from MSCs to coat the microparticles creating synthetic MSCs (synMSCs). Luo et al1 showed the ability of the synMSCs for sustained release of growth factors and their potential for storage. Moreover, the authors demonstrated that synMSCs can increase the proliferative capacity and contractile function of neonatal rat cardiomyocytes in vitro and used an in vivo myocardial infarction model to demonstrate the regenerative potential of the synMSCs.
We think this article advances the knowledge about storage and usage of MSCs …